With this in mind, our data could have significant implications for the development of treatments targeting the CX3CL1/CX3CR1 axis as it suggests that sFKN has a much greater and more consistent impact on mitigating cognitive deficits than membrane-bound forms of the CX3CL1 protein, and thus may be a better therapeutic candidate for treating diseases with a significant cognitive component. Here, CX3CL1 is linked to Cognitive impairment.